odiparcil - CAS 137215-12-4
Catalog number:
137215-12-4
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C15H16O6S
Molecular Weight:
324.35
COA:
Inquire
Targets:
Thrombin
Description:
Odiparcil is a novel thrombin inhibitor as a beta-d-thioxyloside analog originated by Fournier Pharma. It is also a Glycosaminoglycan stimulant. Research for the treatment of Atrial fibrillation, Deep vein thrombosis, Stroke and Thrombosis was discontinued.
Publictions citing BOC Sciences Products
  • >> More
Purity:
98%
Appearance:
Powder
Synonyms:
GSK-424323;4-methyl-7-(((2R,3R,4S,5S)-3,4,5-trihydroxytetrahydro-2H-thiopyran-2-yl)oxy)-2H-chromen-2-one
Solubility:
Soluble in DMSO
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
Atrial fibrillation; Deep vein thrombosis; Stroke; Thrombosis
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
InChIKey:
JRHNIQQUVJOPQC-AQNFWKISSA-N
InChI:
1S/C15H16O6S/c1-7-4-12(17)21-11-5-8(2-3-9(7)11)20-15-14(19)13(18)10(16)6-22-15/h2-5,10,13-16,18-19H,6H2,1H3/t10-,13+,14-,15-/m1/s1
Canonical SMILES:
Cc1cc(=O)oc2c1ccc(c2)O[C@H]3[C@@H]([C@H]([C@@H](CS3)O)O)O
Current Developer:
Originator Fournier Pharma
1.A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis.
Toomey JR1, Abboud MA, Valocik RE, Koster PF, Burns-Kurtis CL, Pillarisetti K, Danoff TM, Erhardt JA. J Thromb Haemost. 2006 Sep;4(9):1989-96.
BACKGROUND: A significant need exists for new chronic oral anticoagulation therapies to replace warfarin. Previous studies have shown that beta-D-xylosides, which prime glycosaminoglycan (GAG) synthesis, have antithrombin and antithrombotic activity. In the following report, a new orally active beta-D-xyloside (odiparcil) has been characterized in a rat model of venous thrombosis and its efficacy and bleeding liability compared to warfarin. Additionally, studies were conducted to investigate odiparcil's ex vivo antithrombin and antiplatelet activity, and also to explore the potential utility of protamine sulfate as a neutralizing agent.
2.Characterization of total plasma glycosaminoglycan levels in healthy volunteers following oral administration of a novel antithrombotic odiparcil with aspirin or enoxaparin.
Myers AL1, Upreti VV, Khurana M, Eddington ND. J Clin Pharmacol. 2008 Oct;48(10):1158-70. doi: 10.1177/0091270008323751. Epub 2008 Aug 29.
Odiparcil is a novel, orally active beta-d-thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events. Its unique mechanism of action is postulated by means of an elevation in circulating endogenous chondroitin sulfate-related glycosaminoglycans (GAGs) levels. The purpose of these 2 separate clinical studies was to evaluate plasma GAG levels in healthy subjects administered odiparcil with either aspirin (ASA) or enoxaparin. Clinical plasma samples were processed and analyzed using validated HPLC bioassays that indirectly estimate GAG levels based on the simultaneous detection of the chondroitin disaccharide derivatives. The concomitant administration of odiparcil with or without ASA resulted in a significant elevation in GAG levels over baseline for both treatment groups. In the other clinical study, the concomitant administration of odiparcil with or without enoxaparin displayed significant increases in plasma DeltaDi-OS, DeltaDi-4S, and total disaccharide levels versus control group.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Thrombin Products


CAS 211914-51-1 Dabigatran

Dabigatran
(CAS: 211914-51-1)

Dabigatran is a very potent anticoagulant, shows that the terminal phenyl can be substituted by the more hydrophilic 2-pyridyl group without substantial loss of...

CAS 137339-65-2 Sfllrnpndkyepf

Sfllrnpndkyepf
(CAS: 137339-65-2)

SFLLRNPNDKYEPF is a synthetic thrombin receptor agonist peptide and causes platelet aggregation (EC50 = 4 μM) and secretion .

VE-1902

VE-1902 is a novel and selective inhibitor of thrombin. Study in vivo and in vitro showed that VE-1902 inhibits thrombin via binding to it reversibly.

H-D-Phe-Pro-arginal
(CAS: 60503-05-1)

H-D-Phe-Pro-arginal is a thrombin inhibitor which is being developed by IVAX for the potential treatment of thromboembolic disorders. It has a similar efficacy ...

CAS 496775-62-3 Eltrombopag Olamine

Eltrombopag Olamine
(CAS: 496775-62-3)

Eltrombopag is a is an agonist of the c-mpl (TpoR) receptor used as treatment for thrombocytopenia.It has been developed for certain conditions that lead to thr...

GYKI14451
(CAS: 69201-89-4)

GYKI14451 is a synthetic tripeptide inhibitor of thrombin. It has anti-atherosclerotic activity.

CAS 872728-81-9 Dabigatran etexilate mesylate

Dabigatran etexilate mesylate
(CAS: 872728-81-9)

Dabigatran etexilate mesylate is the orally active prodrug of dabigatran. It is a reversible and selective, direct thrombin inhibitor (DTI).

Bivalirudin Trifluoroacetate

Bivalirudin is a specific and reversible bivalent direct thrombin inhibitor. Bivalirudin specifically binds to both the catalytic site and to the anion-binding ...

CAS 211915-06-9 Dabigatran Etexilate

Dabigatran Etexilate
(CAS: 211915-06-9)

Dabigatran etexilate(BIBR-1048) is the orally active prodrug of dabigatran; Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) with Ki va...

CAS 74863-84-6 Argatroban

Argatroban
(CAS: 74863-84-6)

Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor.

CAS 30827-99-7 AEBSF HCl

AEBSF HCl
(CAS: 30827-99-7)

AEBSF is a water soluble, irreversible serine protease inhibitor; inhibits proteases like chymotrypsin, kallikrein, plasmin, thrombin, and trypsin.

CAS 192939-46-1 Ximelagatran

Ximelagatran
(CAS: 192939-46-1)

Ximelagatran, an ester prodrug of melagatran, with anticoagulant effect, is the first member of direct thrombin inhibitors that can be taken orally.

CAS 137215-12-4 odiparcil

odiparcil
(CAS: 137215-12-4)

Odiparcil is a novel thrombin inhibitor as a beta-d-thioxyloside analog originated by Fournier Pharma. It is also a Glycosaminoglycan stimulant. Research for th...

CAS 429658-95-7 Dabigatran ethyl ester

Dabigatran ethyl ester
(CAS: 429658-95-7)

Dabigatran ethyl ester is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. Dabigatran provides a stable anticoagulation effect w...

CAS 83997-16-4 GYKI 14166

GYKI 14166
(CAS: 83997-16-4)

Efegatran is a thrombin inhibitor under the development of Eli Lilly. It can be used for the treatment of thromboembolic disorders. No development reported was ...

CAS 141396-28-3 Argatroban

Argatroban
(CAS: 141396-28-3)

Argatroban is an anticoagulant that is a direct thrombin inhibitor. Argatroban was approved in 2000 for prophylaxis or treatment of thrombosis in patients with ...

CAS 871576-03-3 Flovagatran

Flovagatran
(CAS: 871576-03-3)

Flovagatran is a thrombin inhibitor originated by Trigen Holdings AG. In Dec 2010, Phase-II for Thrombosis was discontinued.

GYKI-14451 sulfate
(CAS: 83861-29-4)

GYKI-14451 is a synthetic tripeptide inhibitor of thrombin.It has anti-atherosclerotic activity.

Chemical Structure

CAS 137215-12-4 odiparcil

Quick Inquiry

Verification code

Featured Items